Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Multiple Myeloma (MM)”

156 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 156 results

Testing effectiveness (Phase 2)UnknownNCT03940833
What this trial is testing

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Who this might be right for
Multiple Myeloma
Asclepius Technology Company Group (Suzhou) Co., Ltd. 20
Early research (Phase 1)Ended earlyNCT04123418
What this trial is testing

WVT078 in Patients With Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma (MM)
Novartis Pharmaceuticals 56
Early research (Phase 1)Looking for participantsNCT06799026
What this trial is testing

Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapse Multiple MyelomaRefractory Multiple Myeloma
David Avigan 25
Testing effectiveness (Phase 2)Study completedNCT03439280
What this trial is testing

Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Who this might be right for
Relapsed/RefractoryMultiple Myeloma
Millennium Pharmaceuticals, Inc. 50
Testing effectiveness (Phase 2)Study completedNCT03450057
What this trial is testing

Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Hellenic Society of Hematology 38
Testing effectiveness (Phase 2)Study completedNCT05228470
What this trial is testing

Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Who this might be right for
ElranatamabMyelomaMultiple Myeloma+8 more
Pfizer 39
Early research (Phase 1)UnknownNCT05438394
What this trial is testing

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM

Who this might be right for
Multiple Myeloma
Peking University People's Hospital 24
Not applicableUnknownNCT04447573
What this trial is testing

Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd. 20
Early research (Phase 1)Study completedNCT03275103
What this trial is testing

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Who this might be right for
Multiple Myeloma
Genentech, Inc. 355
Early research (Phase 1)Study completedNCT01582295
What this trial is testing

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

Who this might be right for
Multiple Myeloma
Massachusetts General Hospital 4
Testing effectiveness (Phase 2)UnknownNCT05998928
What this trial is testing

A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

Who this might be right for
Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 10
Testing effectiveness (Phase 2)Active Not RecruitingNCT04883242
What this trial is testing

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
University of Washington 30
Early research (Phase 1)Study completedNCT00642954
What this trial is testing

Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Merck Sharp & Dohme LLC 31
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Early research (Phase 1)Study completedNCT02992483
What this trial is testing

Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Novartis Pharmaceuticals 31
Early research (Phase 1)Study completedNCT01456689
What this trial is testing

Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis Pharmaceuticals 79
Very early researchNot Yet RecruitingNCT07539233
What this trial is testing

A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.

Who this might be right for
Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China 24
Very early researchLooking for participantsNCT06045091
What this trial is testing

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Who this might be right for
Multiple MyelomaPlasma Cell Leukemia
Hrain Biotechnology Co., Ltd. 18
Early research (Phase 1)UnknownNCT03706547
What this trial is testing

Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma Progression
Peng Liu 20
Large-scale testing (Phase 3)Study completedNCT01239797
What this trial is testing

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Who this might be right for
LymphomaMultiple Myeloma
Bristol-Myers Squibb 646
Next Page